Pipeline

Our initial focus has been on GLP-1 receptor agonists as they are an increasingly utilized class of drugs for treating type 2 diabetes.

SISU^®

Powerful, versatile technology platform that enables us to tailor, enhance and extend the duration of long-acting injectable small molecule and biomolecule compounds.

Biopolymers

Large Scale medical grade biopolymer production facility

Challenges

Our target is to develop an optimal platform formulation technology.